Antibody Persistence and Booster Response in Adolescents and Young Adults 4 and 7.5 Years After Immunization with 4CMenB Vaccine
Data on duration of protection against invasive meningococcal disease post-vaccination with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) are limited. We evaluated bactericidal activity persistence in adolescents/young adults up to 7.5 years post-primary vaccination with 4CMenB, and response to a booster dose compared with vaccine-naïve controls. This open-label, multicentre study enrolled 15-24 year-old-previously vaccinated…
